Overall survival and PD-L1 expression in patients with recurrent or metastatic head and neck cancer treated with nivolumab

医学 无容量 内科学 肿瘤科 头颈部癌 头颈部鳞状细胞癌 无进展生存期 接收机工作特性 癌症 临床终点 免疫组织化学 对数秩检验 PD-L1 生存分析 胃肠病学 总体生存率 免疫疗法 临床试验
作者
Isaku Okamoto,Hiroki Sato,Kiyoaki Tsukahara
出处
期刊:Auris Nasus Larynx [Elsevier BV]
卷期号:47 (4): 676-686 被引量:13
标识
DOI:10.1016/j.anl.2020.04.001
摘要

Objective Our facility measures programmed cell death ligand 1 (PD-L1) expression in all patients before administering nivolumab. The aim of the present study is to clarify the association between overall survival (OS) and PD-L1 expression. Patients and Methods Subjects in this study were 52 patients with R/M-HNC cancer (45 men, 7 women) administered nivolumab in our facility between June 1, 2017 and January 31, 2019. Mean age was 62.2 years (median, 65 years; range, 28–81 years). Histopathological type was squamous cell carcinoma (SCC) in 48 cases, and non-SCC in 4 cases. We set OS as the primary endpoint and progression-free survival (PFS), overall response rate (ORR), association of OS and PD-L1 expression and association of PFS and PD-L1 expression as secondary endpoints. The cut-off for PD-L1 expression was set using the receiver operating characteristic (ROC) curve. We compared OS, PES and ORR using this PD-L1 cut-off for all patients and for the SCC group. OS and PFS were calculated using Kaplan-Meier methods. The log-rank test was used for statistical analysis, with values of p < 0.05 taken as significant. For PD-L1 immunohistochemistry assays, Dako 28-8 antibody was used. Results In the all-patients group, median OS was 9.6 months and 1-year OS rate was 40.4%. Median PFS was 4.0 months and 1-year PFS rate was 37.8%. The cut-off value of PD-L1 expression for OS was 40% for all patients and the SCC group. When PD-L1 expression was ≥40%, OS was significantly better in both all patients and the SCC group (p = 0.004, 0.007). The cut-off value of PD-L1 expression for PFS was also 40%. When PD-L1 expression was ≥40%, PFS was better in all patients and the SCC group (P = 0.003, 0.009). In the all-patients group, ORR was 19.2% and disease control rate (DCR) was 44.2%. When PD-L1 expression was ≥40%, ORR was 44.4% and DCR 83.3%. Conclusion In the present study, when PD-L1 expression was high (≥40%), OS was significantly better (p = 0.004). This finding has not been reported in other research on R/M-HNC. PFS and ORR were also better with high PD-L1 expression. Regarding patterns of progression with a PD-L1 expression cut-off of 40%, hyperprogression was significantly more frequent for PD-L1 expression <40% (p = 0.039). Therefore, high PD-L1 expression could offer a predictor of prognosis and efficacy for nivolumab. The present findings may prove useful in considering treatment strategies.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
nbing发布了新的文献求助10
1秒前
1秒前
YamDaamCaa应助饱满的靖易采纳,获得30
1秒前
慕青应助霸王丸采纳,获得30
1秒前
淡淡从安发布了新的文献求助100
1秒前
嬛嬛发布了新的文献求助10
2秒前
252525发布了新的文献求助10
2秒前
小二郎应助ly采纳,获得10
2秒前
2秒前
kkaky发布了新的文献求助10
2秒前
4秒前
南宫古伦完成签到 ,获得积分10
4秒前
5秒前
斯文败类应助zjl900111采纳,获得10
5秒前
菠萝发布了新的文献求助10
5秒前
科目三应助bairimao采纳,获得10
5秒前
yizhi猫发布了新的文献求助10
6秒前
LI发布了新的文献求助10
6秒前
6秒前
在水一方应助光亮嵩采纳,获得30
6秒前
zyzhnu完成签到,获得积分10
7秒前
BING发布了新的文献求助10
7秒前
sos发布了新的文献求助10
7秒前
7秒前
嬛嬛完成签到,获得积分10
8秒前
Frankll发布了新的文献求助150
9秒前
呼呼发布了新的文献求助10
9秒前
9秒前
苹果笑寒发布了新的文献求助20
11秒前
栗子完成签到 ,获得积分10
11秒前
彭于晏应助热塑性哈士奇采纳,获得10
11秒前
momo发布了新的文献求助10
12秒前
欧拉完成签到,获得积分10
12秒前
和平发展发布了新的文献求助10
12秒前
12秒前
qing完成签到,获得积分10
12秒前
慕青应助苹果板栗采纳,获得10
13秒前
13秒前
沉默成沨完成签到,获得积分10
13秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 360
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3971091
求助须知:如何正确求助?哪些是违规求助? 3515797
关于积分的说明 11179488
捐赠科研通 3250872
什么是DOI,文献DOI怎么找? 1795536
邀请新用户注册赠送积分活动 875891
科研通“疑难数据库(出版商)”最低求助积分说明 805207